| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:44 UTC |
|---|
| HMDB ID | HMDB0014757 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Imatinib |
|---|
| Description | Imatinib is a drug used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells. |
|---|
| Structure | CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1 InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) |
|---|
| Synonyms | | Value | Source |
|---|
| 4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide | ChEBI | | alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide | ChEBI | | STI 571 | ChEBI | | Glamox | Kegg | | a-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide | Generator | | Α-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide | Generator | | Imatinib methansulfonate | HMDB | | STI-571 | HMDB | | Glivec | HMDB | | Methanesulfonate, imatinib | HMDB | | Imatinib methanesulfonate | HMDB | | Imatinib mesylate | HMDB | | Gleevec | HMDB | | Mesylate, imatinib | HMDB | | alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide | HMDB |
|
|---|
| Chemical Formula | C29H31N7O |
|---|
| Average Molecular Weight | 493.6027 |
|---|
| Monoisotopic Molecular Weight | 493.259008649 |
|---|
| IUPAC Name | N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)-4-[(4-methylpiperazin-1-yl)methyl]benzamide |
|---|
| Traditional Name | imatinib |
|---|
| CAS Registry Number | 152459-95-5 |
|---|
| SMILES | CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1 |
|---|
| InChI Identifier | InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) |
|---|
| InChI Key | KTUFNOKKBVMGRW-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as oxazolidinediones. Oxazolidinediones are compounds containing an oxazolidine ring which bears two ketones. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Azolidines |
|---|
| Sub Class | Oxazolidines |
|---|
| Direct Parent | Oxazolidinediones |
|---|
| Alternative Parents | |
|---|
| Substituents | - Oxazolidinedione
- Dicarboximide
- Carbamic acid ester
- Carbonic acid derivative
- Oxacycle
- Azacycle
- Carboxylic acid derivative
- Hydrocarbon derivative
- Organopnictogen compound
- Organic oxygen compound
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Carbonyl group
- Organic oxide
- Aliphatic heteromonocyclic compound
|
|---|
| Molecular Framework | Aliphatic heteromonocyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 226 °C (mesylate salt) | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.015 g/L | Not Available | | LogP | 3 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 214.6 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.62 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.3086 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.79 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 63.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 766.7 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 121.9 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 143.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 126.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 61.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 293.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 400.7 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 193.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 715.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 57.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 764.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 208.2 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 273.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 223.1 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 347.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 242.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Imatinib,1TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C)C=C1NC1=NC=CC(C2=CC=CN=C2)=N1 | 4439.7 | Semi standard non polar | 33892256 | | Imatinib,1TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C)C=C1NC1=NC=CC(C2=CC=CN=C2)=N1 | 2643.1 | Standard non polar | 33892256 | | Imatinib,1TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C)C=C1NC1=NC=CC(C2=CC=CN=C2)=N1 | 5873.1 | Standard polar | 33892256 | | Imatinib,1TMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C | 4540.1 | Semi standard non polar | 33892256 | | Imatinib,1TMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C | 2926.8 | Standard non polar | 33892256 | | Imatinib,1TMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C | 5795.6 | Standard polar | 33892256 | | Imatinib,2TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C | 4272.2 | Semi standard non polar | 33892256 | | Imatinib,2TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C | 2829.6 | Standard non polar | 33892256 | | Imatinib,2TMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C | 5475.5 | Standard polar | 33892256 | | Imatinib,1TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C=C1NC1=NC=CC(C2=CC=CN=C2)=N1 | 4604.1 | Semi standard non polar | 33892256 | | Imatinib,1TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C=C1NC1=NC=CC(C2=CC=CN=C2)=N1 | 2843.4 | Standard non polar | 33892256 | | Imatinib,1TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C=C1NC1=NC=CC(C2=CC=CN=C2)=N1 | 5915.7 | Standard polar | 33892256 | | Imatinib,1TBDMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 4693.6 | Semi standard non polar | 33892256 | | Imatinib,1TBDMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 3126.6 | Standard non polar | 33892256 | | Imatinib,1TBDMS,isomer #2 | CC1=CC=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 5815.5 | Standard polar | 33892256 | | Imatinib,2TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 4603.2 | Semi standard non polar | 33892256 | | Imatinib,2TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 3324.7 | Standard non polar | 33892256 | | Imatinib,2TBDMS,isomer #1 | CC1=CC=C(N(C(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)[Si](C)(C)C(C)(C)C)C=C1N(C1=NC=CC(C2=CC=CN=C2)=N1)[Si](C)(C)C(C)(C)C | 5509.4 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Imatinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-01bd-9863300000-bf69c843c9ad9179bcdb | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Imatinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-qTof , Positive-QTOF | splash10-0006-0036900000-e06abe669a9b1b57e2c3 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-0006-0000900000-3974d719909aa7a75039 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-0006-0000900000-dd386ae17930da36c11f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-0f6x-0159500000-576f293e026deaa1ec7f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-0ik9-0495000000-06102c4afd3c2e88cf87 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-03ka-0971000000-b487f693e17cba198e37 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-05fs-0930000000-9319811c561fd5cc8f2f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-0159-4910000000-25480eb9451aee843c26 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-014i-9000000000-0638bee21655c0e0ca00 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , negative-QTOF | splash10-014i-9000000000-76f9b62b017fe8241e67 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-0006-0000900000-9825e12c65f9bf36d72f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-0006-1029200000-acd76280414e767f0280 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-0006-2269000000-f55e5c707c9de5ba2d0f | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-00ba-3494000000-19e7d8361f050ec8b637 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-00ba-3693000000-c1e011113081e3341bba | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-0596-5981000000-a0f689cd067d45644bcd | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-0f9f-5930000000-71f05e812cf29e11cc69 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-00ku-5910000000-3f91ea6a6f7402767a78 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Imatinib LC-ESI-QFT , positive-QTOF | splash10-029i-7900000000-507c771376ea4b799b6d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imatinib 10V, Positive-QTOF | splash10-0006-0144900000-2c1268fe741d4e07f7a4 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imatinib 20V, Positive-QTOF | splash10-00kf-0698300000-b23d90ff38472b542f79 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imatinib 40V, Positive-QTOF | splash10-02tc-3911000000-88d44a81ccb6cf024cbc | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imatinib 10V, Negative-QTOF | splash10-0006-1110900000-e7ed25c6dc02f44eff1e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imatinib 20V, Negative-QTOF | splash10-002g-7534900000-56f8e35b9d7416fcc95f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Imatinib 40V, Negative-QTOF | splash10-0006-9610100000-772d808632d87b2ad3e5 | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL: Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006 Jul 15;107(2):345-51. [PubMed:16779792 ]
- Vigneri P, Wang JY: Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001 Feb;7(2):228-34. [PubMed:11175855 ]
- Deininger MW, Druker BJ: Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003 Sep;55(3):401-23. Epub 2003 Jul 17. [PubMed:12869662 ]
- Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004 May;24(5):935-42. Epub 2004 Feb 26. [PubMed:14988091 ]
- Reeves PM, Bommarius B, Lebeis S, McNulty S, Christensen J, Swimm A, Chahroudi A, Chavan R, Feinberg MB, Veach D, Bornmann W, Sherman M, Kalman D: Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat Med. 2005 Jul;11(7):731-9. Epub 2005 Jun 26. [PubMed:15980865 ]
|
|---|